4 HMO Stocks to Watch Despite Continued Industry Headwinds
The Medical-HMO industry is aided by rising health insurance premiums and strategic M&A moves, but faces margin pressure from high-tech costs and staffing shortages. UNH, CI, HUM and MOH are likely to navigate industry storms.
Why Cigna (CI) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cigna seeks to disqualify FTC Chair Lina Khan from insulin case because of alleged bias
Cigna said that Khan, along with Commissioners Rebecca Kelly Slaughter and Alvaro Bedoya, have made repeated and incorrect prejudgments that show bias against pharmacy-benefit managers.
Will Cigna (CI) Beat Estimates Again in Its Next Earnings Report?
Cigna (CI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CVS, Cigna unveil Medicare Advantage plans for 2025
CVS Health and Cigna on Tuesday released details on their government-backed health insurance plans for next year for people aged 65 and above, saying some members would pay $0 premium monthly for prescription drugs.
Here's Why Cigna (CI) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cigna: This Dividend Grower Could Be Worth Buying Now
The managed care company's total revenue and non-GAAP EPS climbed higher in the second quarter. Cigna's dividend is comfortably covered by non-GAAP EPS and free cash flow. Shares of the stock appear to be priced at a 17% discount to fair value.
Are CVS Health, Cigna, and UnitedHealth Group Stocks Bad News Buys With the FTC's PBM Crackdown?
The FTC is suing CVS Health, Cigna, and UnitedHealth Group because of alleged uncompetitive PBM practices. Their PBM units are major revenue sources for all three healthcare companies.
Pharmacy benefit managers respond to FTC's lawsuit over insulin drug prices
CNBC's Eamon Javers joins 'The Exchange' to report the latest on the FTC's lawsuit against drug middlemen for allegedly inflating insulin prices.
Explainer: Why are US pharmacy benefit managers under fire?
The U.S. Federal Trade Commission said on Friday it was suing the country's three largest pharmacy benefit managers, accusing them of abusing their power and rigging the pharmaceutical supply chain to artificially inflate the cost of insulin.
Cigna: Growth From Specialty Pharmacy And Care; Initiate With 'Buy'
I am initiating a 'Buy' rating for Cigna with a one-year target price of $450 per share, driven by strong Specialty and Cigna Healthcare growth. Cigna's Specialty Pharmacy and Care Market, accounting for 30% of revenue, is poised for above-market growth due to its leadership in the chronic market and biosimilar offerings. Cigna Healthcare's divestiture of low-margin Medicare businesses will allow focus on employer-sponsored plans, targeting small and mid-size enterprises, contributing to 7% organic revenue growth.
Cigna Launches E-Treatment Service for Convenient Patient Access
As the telehealth sector is projected to reach $450 billion by 2032, Cigna Healthcare recently launched an “E-Treatment” option via MDLIVE, offering customers access to urgent care from board-certified doctors without the need for direct phone or video consultations.
